CTOs on the Move

ADMEDES SCHUESSLER GmbH

www.admedes.com

 
ADMEDES SCHUESSLER GmbH is a West Chester, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.admedes.com
  • 808 General Sterling Dr
    West Chester, PA USA 19382
  • Phone: 610.793.2746

Executives

Name Title Contact Details

Similar Companies

Orion Genomics

Orion Genomics is a Saint Louis, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Antibe Therapeutics

Antibe Therapeutics develops safer medications for chronic pain and inflammation. Today, physicians and consumers rely principally on non-steroidal anti-inflammatory drugs (NSAIDs), a $12 billion category of medications that includes brands like Advil, Aleve, Motrin, Celebrex, Voltaren and Aspirin. While effective, NSAIDs can cause gastrointestinal damage and bleeding. To address this serious medical need, Antibe has patented a technology for linking NSAID molecules to hydrogen sulfide molecules. More than a decade of academic and applied research has demonstrated that hydrogen sulfide, when appropriately delivered, can protect the gastrointestinal tract and enhance the anti-inflammatory effectiveness of today’s NSAIDs. Beginning with its IPO in mid-2013, Antibe has raised more than $10 million and initiated human clinical trials of its first drug, aimed at mild to moderate pain.

Switch Therapeutics

Switch Therapeutics is an emerging preclinical stage biotechnology company pioneering a new type of medicine that integrates nucleic acid nanotechnology and RNA interference (RNAi) science with the goal of treating a range of diseases – affecting the central nervous system and systemic indications – with significant unmet needs. Switch`s novel gene knockdown approach is based on technology developed by renowned researchers in the field of RNA from Caltech, Harvard and City of Hope. Based on the scientific discovery of Switch`s co-founders, the company has developed a novel proprietary platform known as CASi (Conditionally Activated siRNAs) that combines advantageous properties of both single and double-stranded RNAs in a single molecule, allowing for cell selective RNAi activity. To date, Switch has raised $52M in funding through Series A, and the company`s South San Francisco based team has continued to grow as its research has advanced.

Faze Medicines

Faze Medicines is a biotechnology company pioneering therapeutics based on the groundbreaking new science of biomolecular condensates.

Proginitor Cell Therapy

Proginitor Cell Therapy is a Mountain View, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.